logo_large_alt

The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), is an international consortium dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.

Latest News
Genomics of Young Lung Cancer ALCMI Study PublishedGenomics of Young Lung Cancer ALCMI Study Published ALCMI's GOYLC study has been published in JTO Clinical and Research Reports. Click here to read the full text article. READ MORE
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy READ MORE